Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt No Debt
RXII's Cash-to-Debt is ranked higher than
78% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. RXII: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
RXII' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.35  Med: No Debt Max: No Debt
Current: No Debt
Interest Coverage No Debt
RXII's Interest Coverage is ranked higher than
70% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. RXII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
RXII' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Piotroski F-Score: 2
Altman Z-Score: -9.04
Beneish M-Score: -4.74
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating Margin % -64368.42
RXII's Operating Margin % is ranked lower than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. RXII: -64368.42 )
Ranked among companies with meaningful Operating Margin % only.
RXII' s Operating Margin % Range Over the Past 10 Years
Min: -64368.42  Med: -13376.29 Max: -5250.38
Current: -64368.42
-64368.42
-5250.38
Net Margin % -64331.58
RXII's Net Margin % is ranked lower than
98% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. RXII: -64331.58 )
Ranked among companies with meaningful Net Margin % only.
RXII' s Net Margin % Range Over the Past 10 Years
Min: -64331.58  Med: -13278.35 Max: -5244.36
Current: -64331.58
-64331.58
-5244.36
ROE % -209.90
RXII's ROE % is ranked lower than
86% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. RXII: -209.90 )
Ranked among companies with meaningful ROE % only.
RXII' s ROE % Range Over the Past 10 Years
Min: -336.41  Med: -179.32 Max: -112.12
Current: -209.9
-336.41
-112.12
ROA % -140.48
RXII's ROA % is ranked lower than
86% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. RXII: -140.48 )
Ranked among companies with meaningful ROA % only.
RXII' s ROA % Range Over the Past 10 Years
Min: -603.25  Med: -152.17 Max: -72.95
Current: -140.48
-603.25
-72.95
ROC (Joel Greenblatt) % -9752.79
RXII's ROC (Joel Greenblatt) % is ranked lower than
83% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. RXII: -9752.79 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
RXII' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -11172.8  Med: -5410.34 Max: -3597.18
Current: -9752.79
-11172.8
-3597.18
3-Year Revenue Growth Rate -80.20
RXII's 3-Year Revenue Growth Rate is ranked lower than
99.99% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. RXII: -80.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
RXII' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -80.2 Max: -67.9
Current: -80.2
3-Year EBITDA Growth Rate -59.70
RXII's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. RXII: -59.70 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
RXII' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -62.8  Med: -59.7 Max: -58.2
Current: -59.7
-62.8
-58.2
3-Year EPS without NRI Growth Rate -61.50
RXII's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. RXII: -61.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
RXII' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.6  Med: -61.5 Max: -54.5
Current: -61.5
-66.6
-54.5
GuruFocus has detected 3 Warning Signs with RXi Pharmaceuticals Corp $RXII.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» RXII's 30-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

RXII Guru Trades in Q2 2016

Jim Simons 142,580 sh (+49.94%)
» More
Q3 2016

RXII Guru Trades in Q3 2016

Jim Simons 181,780 sh (+27.49%)
» More
Q4 2016

RXII Guru Trades in Q4 2016

Jim Simons 229,980 sh (+26.52%)
» More
Q1 2017

RXII Guru Trades in Q1 2017

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with NAS:RXII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:OTCPK:ENDV, NAS:SBOT, OTCPK:BCTXF, NAS:AEZS, NAS:CERU, NAS:PZRX, NAS:XTLB, OTCPK:ZIVO, OTCPK:CGYG, NAS:MBVX, OTCPK:OPNT, NAS:MBRX, OTCPK:ATBPF, OTCPK:MYMX, AMEX:HEB, NAS:SNGX, NAS:BSTG, OTCPK:MATN, NAS:CLSN, NAS:TENX » details
Traded in other countries:44R1.Germany,
Headquarter Location:USA
RXi Pharmaceuticals Corp is a clinical-stage RNAi company developing therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which address significant unmet medical needs.

RXi Pharmaceuticals Corp was incorporated in Delaware on September 8, 2011. It is a biotechnology company focused on discovering and developing therapies addressing high unmet medical needs, in the areas of dermatology and ophthalmology. Its development programs are based on siRNA technology and immunotherapy agents. The clinical development programs include, but are not limited to, its proprietary, self-delivering RNAi (sd-rxRNA) compounds for the treatment of dermal and retinal scarring and an immunodulating agent, Samcyprone, for the treatment of such disorders as alopecia areata, warts and cutaneous metastases of melanoma. In addition to these clinical programs, the Company has a pipeline of discovery and preclinical product candidates in its core therapeutic areas, as well as in other areas of interest. The Company's pipeline, coupled with its extensive patent portfolio, provides for the advancement to further discover and develops therapies either on its own or in collaboration with strategic partners. The Company's first clinical product candidate is RXI-109, a self-delivering RNAi compound being developed for the reduction of dermal scar formation. RXI-109 is designed to reduce the expression of connective tissue growth factor, a critical regulator of several biological pathways involved in fibrosis, including scar formation in the skin. RXI-109 is being developed to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids. The Company competes with Alnylam Pharmaceuticals, Inc., Benitec Limited, Silence Therapeutics plc, Quark Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corporation, Arrowhead Research Corporation, Dicerna Pharmaceuticals, Inc., Sylentis, S.A. and Roche Innovation Center Copenhagen A/S. The Company is subject to federal, state and local regulations relating to the use, handling, storage and disposal of hazardous materials, including chemicals and radioactive and biological materials.

Ratios

vs
industry
vs
history
PB Ratio 1.52
RXII's PB Ratio is ranked higher than
78% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. RXII: 1.52 )
Ranked among companies with meaningful PB Ratio only.
RXII' s PB Ratio Range Over the Past 10 Years
Min: 0.92  Med: 4.83 Max: 50.29
Current: 1.52
0.92
50.29
EV-to-EBIT -0.19
RXII's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. RXII: -0.19 )
Ranked among companies with meaningful EV-to-EBIT only.
RXII' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.7  Med: -1.2 Max: 0.5
Current: -0.19
-7.7
0.5
EV-to-EBITDA -0.20
RXII's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. RXII: -0.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
RXII' s EV-to-EBITDA Range Over the Past 10 Years
Min: -7.8  Med: -1.2 Max: 0.5
Current: -0.2
-7.8
0.5
Current Ratio 4.58
RXII's Current Ratio is ranked lower than
66% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. RXII: 4.58 )
Ranked among companies with meaningful Current Ratio only.
RXII' s Current Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.11 Max: 11.98
Current: 4.58
0.48
11.98
Quick Ratio 4.58
RXII's Quick Ratio is ranked lower than
63% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. RXII: 4.58 )
Ranked among companies with meaningful Quick Ratio only.
RXII' s Quick Ratio Range Over the Past 10 Years
Min: 0.48  Med: 6.11 Max: 11.98
Current: 4.58
0.48
11.98

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -106.60
RXII's 3-Year Average Share Buyback Ratio is ranked lower than
99.99% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. RXII: -106.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
RXII' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -163  Med: -131 Max: -106.6
Current: -106.6
-163
-106.6

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 1.58
RXII's Price-to-Net-Cash is ranked higher than
85% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. RXII: 1.58 )
Ranked among companies with meaningful Price-to-Net-Cash only.
RXII' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0  Med: 6.86 Max: 17.2
Current: 1.58
0
17.2
Price-to-Net-Current-Asset-Value 1.54
RXII's Price-to-Net-Current-Asset-Value is ranked higher than
89% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. RXII: 1.54 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
RXII' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0  Med: 8.35 Max: 40.28
Current: 1.54
0
40.28
Price-to-Tangible-Book 1.54
RXII's Price-to-Tangible-Book is ranked higher than
83% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. RXII: 1.54 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
RXII' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.01  Med: 8.14 Max: 35.79
Current: 1.54
1.01
35.79
Price-to-Median-PS-Value 2.59
RXII's Price-to-Median-PS-Value is ranked lower than
66% of the 584 Companies
in the Global Biotechnology industry.

( Industry Median: 0.98 vs. RXII: 2.59 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
RXII' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 1.05 Max: 6.28
Current: 2.59
0
6.28
Earnings Yield (Greenblatt) % -519.54
RXII's Earnings Yield (Greenblatt) % is ranked lower than
99.99% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. RXII: -519.54 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
RXII' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -571.83  Med: 216.1 Max: 286.8
Current: -519.54
-571.83
286.8

More Statistics

Revenue (TTM) (Mil) $0.02
EPS (TTM) $ -1.57
Beta2.21
Short Percentage of Float11.25%
52-Week Range $0.51 - 3.27
Shares Outstanding (Mil)22.13

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -1.62 -0.75 -0.85
EPS without NRI ($) -1.62 -0.75 -0.85
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for RXII

Headlines

Articles On GuruFocus.com
RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum May 23 2017 
PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology May 22 2017 
RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights May 11 2017 
RXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017 May 04 2017 
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017 Annu May 02 2017 
RXi Pharmaceuticals Corporation Selected to Present at the Cavendish Global Health Impact Forum May 01 2017 
RXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics Confe Apr 25 2017 
RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society Apr 20 2017 
RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes Apr 18 2017 
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate Mar 31 2017 

More From Other Websites
RXi Pharmaceuticals to Present at the 3rd Annual Immuno-Oncology BD&L and Investment Forum May 23 2017
PCI Biotech and RXi Pharmaceuticals Extend Research Collaboration to the Field of Immuno-oncology May 22 2017
Edited Transcript of RXII earnings conference call or presentation 11-May-17 8:30pm GMT May 12 2017
RXi Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Corporate Highlights May 11 2017
RXi Pharmaceuticals to Webcast First Quarter 2017 Financial Results on Thursday, May 11, 2017 May 04 2017
RXi Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology 2017... May 02 2017
RXi Pharmaceuticals Corporation Selected to Present at the Cavendish Global Health Impact Forum May 01 2017
RXi Pharmaceuticals to Present at 19th Annual TIDES: Oligonucleotide and Peptides Therapeutics... Apr 25 2017
RXi Pharmaceuticals to Present an Update on its Consumer Product Development Programs at the Society... Apr 20 2017
RXi Pharmaceuticals Announces New Chief Development Officer and Key Management Changes Apr 18 2017
The Life Sciences Report Examines RXi Pharmaceuticals Receiving Japanese Patent for RNAi Platform Apr 13 2017
RXi Pharmaceuticals Corp. :RXII-US: Earnings Analysis: 2016 By the Numbers : April 3, 2017 Apr 03 2017
RXi Pharmaceuticals to Present at the American Association for Cancer Research Annual Meeting Mar 31 2017
RXi Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Recent Corporate... Mar 30 2017
RXi Pharma Derma Drug Secures Japanese Patent Mar 28 2017
RXi Pharmaceuticals Granted Patent in Japan for Lead Clinical Candidate RXI-109 Mar 28 2017
RXi Pharmaceuticals to Present at the 5th Annual Cancer BioPartnering & Investment Forum Mar 22 2017
RXi Pharmaceuticals to Present at the 2nd Annual Oligonucleotide and Peptide Therapeutics Conference Mar 21 2017
RXi Pharmaceuticals to Webcast Fourth Quarter and Year End 2016 Financial Results on Thursday, March... Mar 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}